Home LiteratureArticle Details
PMID: 36633525 Published · ppublish English Journal Article

Cancer statistics, 2023.

CA: a cancer journal for clinicians ·Vol. 73 ·No. 1 ·2023-00-00 ·Pages 17-48

Siegel RL, Miller KD, Wagle NS, Jemal A

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favorable in men compared to women. For example, lung cancer in women decreased at one half the pace of men (1.1% vs. 2.6% annually) from 2015 through 2019, and breast and uterine corpus cancers continued to increase, as did liver cancer and melanoma, both of which stabilized in men aged 50 years and older and declined in younger men. However, a 65% drop in cervical cancer incidence during 2012 through 2019 among women in their early 20s, the first cohort to receive the human papillomavirus vaccine, foreshadows steep reductions in the burden of human papillomavirus-associated cancers, the majority of which occur in women. Despite the pandemic, and in contrast with other leading causes of death, the cancer death rate continued to decline from 2019 to 2020 (by 1.5%), contributing to a 33% overall reduction since 1991 and an estimated 3.8 million deaths averted. This progress increasingly reflects advances in treatment, which are particularly evident in the rapid declines in mortality (approximately 2% annually during 2016 through 2020) for leukemia, melanoma, and kidney cancer, despite stable/increasing incidence, and accelerated declines for lung cancer. In summary, although cancer mortality rates continue to decline, future progress may be attenuated by rising incidence for breast, prostate, and uterine corpus cancers, which also happen to have the largest racial disparities in mortality.

Keywords
cancer cases cancer statistics death rates incidence mortality
MeSH Terms
Male Humans Female United States/epidemiology Middle Aged Aged Neoplasms/epidemiology Registries Incidence Racial Groups Lung Neoplasms/epidemiology Melanoma Multiple Endocrine Neoplasia Type 1
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Siegel Rebecca L ORCID
Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
Miller Kimberly D ORCID
Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
Wagle Nikita Sandeep ORCID
Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
Jemal Ahmedin
Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
References (123)
123 references, click to expand
  1. Ghoshal S, Rigney G, Cheng D, et al. Institutional surgical response and associated volume trends throughout the COVID-19 pandemic and postvaccination recovery period. JAMA Netw Open. 2022;5(8):e2227443. doi:10.1001/jamanetworkopen.2022.27443
  2. Yabroff KR, Wu XC, Negoita S, et al. Association of the COVID-19 pandemic with patterns of statewide cancer services. J Natl Cancer Inst. 2022;114(6):907-909.
  3. Chen R, Aschmann HE, Chen YH, et al. Racial and ethnic disparities in estimated excess mortality from external causes in the US, March to December 2020. JAMA Intern Med. 2022;182(7):776-778. doi:10.1001/jamainternmed.2022.1461
  4. Woolf SH, Chapman DA, Sabo RT, Zimmerman EB. Excess deaths from COVID-19 and other causes in the US, March 1, 2020, to January 2, 2021. JAMA. 2021;325(17):1786. doi:10.1001/jama.2021.5199
  5. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Data with Delay-Adjustment, 8 Registries, Malignant Only (1975-2019), based on the November 2021 submission. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2022.
  6. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Data, 9 Registries (1975-2018), based on the November 2020 submission. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2021.
  7. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Data, 17 Registries (2000-2019), based on the November 2021 submission. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2022.
  8. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Data with Delay-Adjustment, 17 Registries, Malignant Only (2000-2019), based on the November 2021 submission. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2022.
  9. Statistical Methodology and Applications Branch, National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer Software, version 6.8.0. Surveillance Research Program, Statistical Methodology and Applications Branch, National Cancer Institute; 2022.2.
  10. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America (CiNA) Analytic File, 1995-2019, with Race/Ethnicity, Custom File With County, American Cancer Society Facts & Figures Projection Project (which includes data from the Centers for Disease Control and Prevention’s National Program of Cancer Registries, the Canadian Counsel of Cancer Registry’s Provincial and Territorial Registries, and the National Cancer Institute’s SEER Registries), certified by the NAACCR as meeting high-quality incidence data standards for the specified time periods, submitted December 2021. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2022.
  11. Sherman R, Firth R, Kahl A, et al. Cancer in North America: 2015-2019. Volume Two: Registry-Specific Cancer Incidence in the United States and Canada North American Association of Central Cancer Registries, Inc.; 2022.
  12. Sherman R, Firth R, Kahl A, et al. Cancer in North America: 2015-2019, Volume One: Combined Cancer Incidence for the United States, Canada, and North America. North American Association of Central Cancer Registries, Inc.; 2022.
  13. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All Causes of Death, Total U.S. (1969-2020) (with underlying mortality data provided by the National Center for Health Statistics). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2022.
  14. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97(12 suppl):3133-3275. doi:10.1002/cncr.11380
  15. Murphy SL, Kochanek KD, Xu J, Heron M. Deaths: final data for 2012. Natl Vital Stat Rep. 2015;31(8):1-117.
  16. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer. 2005;103(7):1457-1467. doi:10.1002/cncr.20910
  17. Fritz A, Percy C, Jack A, et al., eds. International Classification of Diseases for Oncology. 3rd ed. World Health Organization; 2000.
  18. Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017;18(6):719-731.
  19. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Volumes I-III. World Health Organization; 2011.
  20. Surveillance Research Program, National Cancer Institute. SEER*Stat software, version 8.4.0. Surveillance Research Program, National Cancer Institute; 2022.
  21. Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program, version 4.9.1.0. Statistical Research and Applications Branch, National Cancer Institute; 2022.
  22. Arias E, Xu J, Curtin S, Bastian B, Tejada-Vera B. Mortality profile of the non-Hispanic American Indian or Alaska Native population, 2019. Natl Vital Stat Rep. 2021;70(12):1-27.
  23. Mariotto AB, Zou Z, Johnson CJ, Scoppa S, Weir HK, Huang B. Geographical, racial and socio-economic variation in life expectancy in the US and their impact on cancer relative survival. PLoS One. 2018;13(7):e0201034. doi:10.1371/journal.pone.0201034
  24. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94(20):1537-1545. doi:10.1093/jnci/94.20.1537
  25. Surveillance, Epidemiology and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America (CiNA) Research Data, 2015-2019, Delay-Adjusted Factors-American Cancer Society Facts & Figures (which includes data from the Centers for Disease Control and Prevention’s National Program of Cancer Registries, the Canadian Council of Cancer Registry’s Provincial and Territorial Registries, and the National Cancer Institute’s SEER Registries), certified by the NAACCR, submitted December 2021. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2022.
  26. Liu B, Zhu L, Zou J, et al. Updated methodology for projecting U.S.- and state-level cancer counts for the current calendar year: part I: spatio-temporal modeling for cancer incidence. Cancer Epidemiol Biomarkers Prev. 2021;30(9):1620-1626. doi:10.1158/1055-9965.epi-20-1727
  27. Miller KD, Siegel RL, Liu B, et al. Updated methodology for projecting U.S.- and state-level cancer counts for the current calendar year: part II: evaluation of incidence and mortality projection methods. Cancer Epidemiol Biomarkers Prev. 2021;30(11):1993-2000. doi:10.1158/1055-9965.epi-20-1780
  28. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 2007;57(1):30-42. doi:10.3322/canjclin.57.1.30
  29. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America (CiNA) Research Data, 2001-2019, Delay-Adjusted Factors-American Cancer Society Facts & Figures (which includes data from the Centers for Disease Control and Prevention’s National Program of Cancer Registries, the Canadian Council of Cancer Registry’s Provincial and Territorial Registries, and the National Cancer Institute’s SEER Registries), certified by the NAACCR, submitted December 2021. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2022.
  30. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Populations-Total United States (1969-2020) <Katrina/Rita Adjustment>-Linked To County Attributes-Total U.S., 1969-2020 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2022.
  31. Jackson SS, Marks MA, Katki HA, et al. Sex disparities in the incidence of 21 cancer types: quantification of the contribution of risk factors. Cancer. 2022;128(19):3531-3540. doi:10.1002/cncr.34390
  32. Choi YJ, Lee DH, Han KD, et al. Adult height in relation to risk of cancer in a cohort of 22, 809, 722 Korean adults. Br J Cancer. 2019;120(6):668-674. doi:10.1038/s41416-018-0371-8
  33. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011;12(8):785-794. doi:10.1016/s1470-2045(11)70154-1
  34. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626-638.
  35. Islami F, Sauer AG, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable factors in the United States in 2014. CA Cancer J Clin. 2018;68(1):31-54. doi:10.3322/caac.21440
  36. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548-552. doi:10.1001/jama.1995.03520310046028
  37. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America (CiNA) Research Data, 1998-2019, Delay-Adjusted Factors-American Cancer Society Facts & Figures (which includes data from the Centers for Disease Control and Prevention’s National Program of Cancer Registries, the Canadian Council of Cancer Registry’s Provincial and Territorial Registries, and the National Cancer Institute’s SEER Registries), certified by the NAACCR, submitted December 2021. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2022.
  38. Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314(19):2054-2061. doi:10.1001/jama.2015.14905
  39. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134. doi:10.7326/0003-4819-157-2-201207170-00459
  40. Borregales LD, DeMeo G, Gu X, et al. Grade migration of prostate cancer in the United States during the last decade. J Natl Cancer Inst. 2022;114(7):1012-1019. doi:10.1093/jnci/djac066
  41. Fenton J, Weyrick M, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Report no. 17-05229-EF-1. Agency for Healthcare Research and Quality; 2018.
  42. U.S. Preventive Services Task Force; Grossman DC, Curry SJ, et al. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913.
  43. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767-1777. doi:10.1056/nejmoa1801993
  44. Nordstrom T, Discacciati A, Bergman M, et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021;22(9):1240-1249. doi:10.1016/s1470-2045(21)00348-x
  45. Sherer MV, Qiao EM, Kotha NV, Qian AS, Rose BS. Association between prostate-specific antigen screening and prostate cancer mortality among non-Hispanic Black and non-Hispanic White US veterans. JAMA Oncol. 2022;8(10):1471-1476. doi:10.1001/jamaoncol.2022.297
  46. Basourakos SP, Gulati R, Vince RA, et al. Harm-to-benefit of three decades of prostate cancer screening in Black men. NEJM Evid. 2022;1(6):EVIDoa2200031. doi:10.1056/evidoa2200031
  47. Awasthi S, Grass GD, Torres-Roca J, et al. Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease. J Natl Cancer Inst. Published online September 2, 2022. 10.1093/jnci/djac162
  48. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. Published online October 3, 2022. 10.3322/caac.21754
  49. Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 2018;27(10):1214-1222. doi:10.1158/1055-9965.epi-18-0098
  50. Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health. 2019;4(3):e137-e147. doi:10.1016/s2468-2667(18)30267-6
  51. U.S. Preventive Services Task Force; Bibbins-Domingo K, Grossman DC, et al. Screening for thyroid cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2017;317(18):1882-1887.
  52. Haugen BR. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017;123(3):372-381. doi:10.1002/cncr.30360
  53. Furuya-Kanamori L, Bell KJL, Clark J, Glasziou P, Doi SAR. Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol. 2016;34(30):3672-3679. doi:10.1200/jco.2016.67.7419
  54. LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO, Davies L. Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex in US thyroid cancer incidence compared with a meta-analysis of subclinical thyroid cancer rates at autopsy. JAMA Intern Med. 2021;181(10):1351. doi:10.1001/jamainternmed.2021.4804
  55. Harris JE. Cigarette smoking among successive birth cohorts of men and women in the United States during 1900-80. J Natl Cancer Inst. 1983;71(3):473-479.
  56. Jemal A, Ma J, Rosenberg PS, Siegel R, Anderson WF. Increasing lung cancer death rates among young women in southern and midwestern states. J Clin Oncol. 2012;30(22):2739-2744. doi:10.1200/jco.2012.42.6098
  57. Siegel RL, Torre LA, Soerjomataram I, et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut. 2019;68(12):2179-2185. doi:10.1136/gutjnl-2019-319511
  58. Siegel RL, Miller KD, Jemal A. Colorectal cancer mortality rates in adults aged 20 to 54 years in the United States, 1970-2014. JAMA. 2017;318(6):572-574. doi:10.1001/jama.2017.7630
  59. Miller KD, Ortiz AP, Pinheiro PS, et al. Cancer statistics for the US Hispanic/Latino population, 2021. CA Cancer J Clin. 2021;71(6):466-487. doi:10.3322/caac.21695
  60. Ortiz AP, Ortiz-Ortiz KJ, Colon-Lopez V, et al. Incidence of cervical cancer in Puerto Rico, 2001-2017. JAMA Oncol. 2021;7(3):456-458. doi:10.1001/jamaoncol.2020.7488
  61. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664-670. doi:10.1002/ijc.30716
  62. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
  63. Mix JM, Van Dyne EA, Saraiya M, Hallowell BD, Thomas CC. Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15-29 years in the United States, 1999-2017: an ecologic study. Cancer Epidemiol Biomarkers Prev. 2021;30(1):30-37. doi:10.1158/1055-9965.epi-20-0846
  64. Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE. Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018. Ann Intern Med. 2022;175(7):918-926. doi:10.7326/m21-3798
  65. Lei J, Ploner A, Elfstrom KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340-1348. doi:10.1056/nejmoa1917338
  66. Falcaro M, Castanon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084-2092. doi:10.1016/s0140-6736(21)02178-4
  67. Kreimer AR, Sampson JN, Porras C, et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. J Natl Cancer Inst. 2020;112(10):1038-1046. doi:10.1093/jnci/djaa011
  68. Rodriguez AM, Zeybek B, Vaughn M, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study. Cancer. 2020;126(8):1656-1667. doi:10.1002/cncr.32700
  69. Man I, Georges D, de Carvalho TM, et al. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study. Lancet Oncol. 2022. doi:10.1016/S1470-2045(22)00543-5
  70. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022: conclusions and recommendations. Wkly Epidemiol Rec. 2022;97(24):261-276.
  71. Pingali C, Yankey D, Elam-Evans LD, et al. National vaccination coverage among adolescents aged 13-17 years-National Immunization Survey-Teen, United States, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(35):1101-1108. doi:10.15585/mmwr.mm7135a1
  72. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol. 2010;37(3):202-215. doi:10.1053/j.seminoncol.2010.05.006
  73. O'Grady TJ, Gates MA, Boscoe FP. Thyroid cancer incidence attributable to overdiagnosis in the United States 1981-2011. Int J Cancer. 2015;137(11):2664-2673. doi:10.1002/ijc.29634
  74. Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186-e193. doi:10.1016/s2352-3026(15)00048-4
  75. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002-1014. doi:10.1016/s0140-6736(21)01206-x
  76. Berk-Krauss J, Stein JA, Weber J, Polsky D, Geller AC. New systematic therapies and trends in cutaneous melanoma deaths among US Whites, 1986-2016. Am J Public Health. 2020;110(5):731-733. doi:10.2105/ajph.2020.305567
  77. Gallicchio L, Devasia TP, Tonorezos E, Mollica MA, Mariotto A. Estimation of the numbers of individuals living with metastatic cancer in the United States. J Natl Cancer Inst. Published online August 22, 2022. doi:10.1093/jnci/djac158
  78. Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. Published online September 12, 2022. doi:10.1056/NEJMoa2209831
  79. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973-1985. doi:10.1056/nejmoa2202170
  80. Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640-649. doi:10.1056/nejmoa1916623
  81. Muthusamy B, Patil PD, Pennell NA. Perioperative systemic therapy for resectable non-small cell lung cancer. J Natl Compr Cancer Netw. 2022;20(8):953-961. doi:10.6004/jnccn.2022.7021
  82. Potter AL, Rosenstein AL, Kiang MV, et al. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. BMJ. 2022;376:e069008. doi:10.1136/bmj-2021-069008
  83. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708
  84. Rami-Porta R, Call S, Dooms C, et al. Lung cancer staging: a concise update. Eur Respir J. 2018;51(5):1800190. doi:10.1183/13993003.00190-2018
  85. Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med. 2018;18(suppl 2):s41-s46. doi:10.7861/clinmedicine.18-2-s41
  86. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-1905. doi:10.1056/nejmoa1915745
  87. McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother's cancer. Cancer. 2016;122(18):2787-2798. doi:10.1002/cncr.30094
  88. Fiorica JV. The role of topotecan in the treatment of advanced cervical cancer. Gynecol Oncol. 2003;90(3 pt 2):S16-S21. doi:10.1016/s0090-8258(03)00465-7
  89. Wan YL, Beverley-Stevenson R, Carlisle D, et al. Working together to shape the endometrial cancer research agenda: the top ten unanswered research questions. Gynecol Oncol. 2016;143(2):287-293. doi:10.1016/j.ygyno.2016.08.333
  90. National Cancer Institute. NCI Funded Research Portfolio: FY 2018 Research Funding by Cancer Type. Accessed October 14, 2022. https://fundedresearch.cancer.gov/nciportfolio/search/funded?fy=PUB2018%26type=site
  91. Clarke MA, Devesa SS, Hammer A, Wentzensen N. Racial and ethnic differences in hysterectomy-corrected uterine corpus cancer mortality by stage and histologic subtype. JAMA Oncol. 2022;8(6):895-903. doi:10.1001/jamaoncol.2022.0009
  92. Jamieson A, Huvila J, Thompson EF, et al. Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification. Gynecol Oncol. 2022;165(2):201-214. doi:10.1016/j.ygyno.2022.02.001
  93. Nero C, Pasciuto T, Cappuccio S, et al. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: a propensity score-matched analysis. Cancer. 2022;128(15):2898-2907. doi:10.1002/cncr.34331
  94. Hu K, Wang W, Liu X, Meng Q, Zhang F. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy. Radiat Oncol. 2018;13(1):249. doi:10.1186/s13014-018-1197-5
  95. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005;103(6):1258-1264. doi:10.1002/cncr.20877
  96. Chow WH, Shuch B, Linehan WM, Devesa SS. Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer. 2013;119(2):388-394. doi:10.1002/cncr.27690
  97. Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017;109(9):djx030. doi:10.1093/jnci/djx030
  98. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000;283(22):2975-2978. doi:10.1001/jama.283.22.2975
  99. Negoita S, Feuer EJ, Mariotto A, et al. Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124(13):2801-2814. doi:10.1002/cncr.31549
  100. Jemal A, Culp MB, Ma J, Islami F, Fedewa SA. Prostate cancer incidence 5 years after U.S. Preventive Services Task Force recommendations against screening. J Natl Cancer Inst. 2021;113(1):64-71. doi:10.1093/jnci/djaa068
  101. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175-181. doi:10.1007/s10552-007-9083-8
  102. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167(7):449-455.
  103. Masters RK, Aron LY, Woolf SH. Changes in life expectancy between 2019 and 2021 in the United States and 21 peer countries. medRxiv. Preprint posted online June 1, 2022. doi:10.1101/2022.04.05.22273393
  104. Nelson DE, Mowery P, Asman K, et al. Long-term trends in adolescent and young adult smoking in the United States: metapatterns and implications. Am J Public Health. 2008;98(5):905-915. doi:10.2105/ajph.2007.115931
  105. Islami F, Guerra CE, Minihan A, et al. American Cancer Society's report on the status of cancer disparities in the United States, 2021. CA Cancer J Clin. 2022;72(2):112-143. doi:10.3322/caac.21703
  106. Gupta A, Omeogu CH, Islam JY, Joshi AR, Akinyemiju TF. Association of area-level socioeconomic status and non-small cell lung cancer stage by race/ethnicity and health care-level factors: analysis of the National Cancer Database. Cancer. 2022;128(16):3099-3108. doi:10.1002/cncr.34327
  107. Wang X, Brown DS, Cao Y, Ekenga CC, Guo S, Johnson KJ. The impact of health insurance coverage on racial/ethnic disparities in US childhood and adolescent cancer stage at diagnosis. Cancer. 2022;128(17):3196-3203. doi:10.1002/cncr.34368
  108. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54(2):78-93. doi:10.3322/canjclin.54.2.78
  109. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of Blacks and Whites after a cancer diagnosis. JAMA. 2002;287(16):2106-2113. doi:10.1001/jama.287.16.2106
  110. Bailey ZD, Krieger N, Agenor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453-1463. doi:10.1016/s0140-6736(17)30569-x
  111. Commission on Social Determinants of Health, World Health Organization. Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health. World Health Organization; 2008.
  112. Braveman P, Gottlieb L. The social determinants of health: it's time to consider the causes of the causes. Public Health Rep. 2014;129(suppl 2):19-31. doi:10.1177/00333549141291s206
  113. Pinheiro LC, Reshetnyak E, Akinyemiju T, Phillips E, Safford MM. Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study. Cancer. 2021;128(1):122-130. doi:10.1002/cncr.33894
  114. Lopez L 3rd, Hart LH 3rd, Katz MH. Racial and ethnic health disparities related to COVID-19. JAMA. 2021;325(8):719-720. doi:10.1001/jama.2020.26443
  115. Shiels MS, Haque AT, Haozous EA, et al. Racial and ethnic disparities in excess deaths during the COVID-19 pandemic, March to December 2020. Ann Intern Med. 2021;174(12):1693-1699. doi:10.7326/m21-2134
  116. Richman I, Tessier-Sherman B, Galusha D, Oladele CR, Wang K. Breast cancer screening during the COVID-19 pandemic: moving from disparities to health equity. J Natl Cancer Inst. 2022. doi:10.1093/jnci/djac172
  117. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2022. American Cancer Society; 2022.
  118. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases. Human papillomavirus vaccination coverage among adolescents (13-17 years). Accessed September 21, 2021. https://data.cdc.gov/Teen-Vaccinations/Vaccination-Coverage-among-Adolescents-13-17-Years/ee48-w5t6/data
  119. Nguyen BT, Han X, Jemal A, Drope J. Diet quality, risk factors and access to care among low-income uninsured American adults in states expanding Medicaid vs. states not expanding under the affordable care act. Prev Med. 2016;91:169-171. doi:10.1016/j.ypmed.2016.08.015
  120. Sommers BD, Gawande AA, Baicker K. Health insurance coverage and health-what the recent evidence tells us. N Engl J Med. 2017;377(6):586-593. doi:10.1056/nejmsb1706645
  121. Kantarjian HM, Keating MJ, Freireich EJ. Toward the potential cure of leukemias in the next decade. Cancer. 2018;124(22):4301-4313. doi:10.1002/cncr.31669
  122. Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol. 2011;8(7):417-424. doi:10.1038/nrclinonc.2011.77
  123. Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 2016;66(3):182-202. doi:10.3322/caac.21335
Article Info
Journal
CA: a cancer journal for clinicians
Abbr.
CA Cancer J Clin
ISSN
1542-4863
DOI
10.3322/caac.21763
Published
2023-00-00
Pages
17-48
Language
English
Region
United States
NLM ID
0370647
Subset
IM
External Links
PubMed source DOI: 10.3322/caac.21763 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2